Suchergebnisse

Ergebnisse 1 - 10 von 10 :

  • pharmacokinetics x
  • Sozialwissenschaften x
  • Klinische Medizin x
Alle zurücksetzen
Association of Single-Nucleotide Polymorhism C3435T in the ABCB1 Gene with Opioid Sensitivity in Treatment of Postoperative Pain

brain opioid receptor availability in central and peripheral neuropathic pain. Pain. 2007 Jan; 127(1–2): 183–94. 5. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 2006; 234: 4–33. 51. 6. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 2006; 112: 457–473. 52. 7. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Thornton N, Folayan GO, Githang’s J, Indalo A, Ofori-Adjei D, Price-Evans DA, McLeod HL. MDR1

Open access
in PRILOZI
Generic Drugs – Decreasing Costs and Room for Increased Number of Kidney Transplantations

nonadherence. Am J Transplant. 2012; 12(2): 388-99. 22. Vítko S, Ferkl M. Interchangeability of ciclosporin formulations in stable adult renal transplant recipients: comparison of Equoral and Neoral capsules in an international, multicenter, randomized, open-label trial. Kidney Int Suppl. 2010; (115): S12-6. 23. Alloway RR, Sadaka B, Trofe-Clark J, et al. A Randomized Pharmacokinetic Study of Generic Tacrolimus Versus Reference Tacrolimus in Kidney Transplant Recipients. Am J Transplant. 2012; 12(10): 2825-2831. 24. Melilli E

Open access
in PRILOZI
Evaluation of Correlation Between the Pharmacogenetic Profiles of Risperidone Treated Psychiatry Patients with Plasma and Urine Concentration of Risperidone and its Active Moiety 9-OH Risperidone Determined with Optimized Bioanalytical LC Method

, Bravaccio C, Radice S, Capuano A. The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions. Pharmacogenomics J. 2018 May 22; 18(3): 422–430. 4. Vandenberghe F, Guidi M, Choong E, von Gunten A, Conus P, Csajka C, Eap CB. Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort. Clin Pharmacokinet. 2015 Dec; 54(12): 1259–72. 5. Bork JA, Rogers T, Wedlund PJ, de Leon J. A pilot study on risperidone

Open access
in PRILOZI
High Performance Liquid Chromatographic Method for Direct Determination of Diazepam in Whole Blood and Serum – Optimization of Solid-Phase Extraction Method

REFERENCES 1. Shorvon S, Perucca E, Engel J., Jr. The treatment of epilepsy. 3. UK: Wiley-Blackwell West Sussex; 2009. 2. Sruthi A, Tejaswi P, Thanuja N, Sudheer Kumar D, Vivek Sagar V. Simple RP-HPLC method for estimation of diazepam in tablet dosage form. J Pharm Res 2013; 6(1):140-144 3. Eatman FB, Colburn WA, Boxenbaum HG, Posmanter HN, Weinfeld RE, Ronfeld R, Weissman L, Moore JD, Gibaldi M, Kaplan SA. Pharmacokinetics of diazepam following multiple-dose oral administration to healthy human subjects. J Pharmacokinet Biopharm. 1977; (5

Open access
in PRILOZI
Genotype Variability and Haplotype Profile of Abcb1 (Mdr1) Gene Polymorphisms in Macedonian Population

Res. 2008; 58: 344-347. 12. Uhr M, Grauer MT, Yassouridis A and Ebinger M. Blood- brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls. J Psychiatr Res. 2007; 41: 179-188. 13. Gex-Fabry M, Eap CB, Oneda B, Gervasoni N, Aubry JM, Bondolfi G, et al. CYP2D6 and ABCB1 genetic variability: Influence on paroxetine plasma level and therapeutic response. Ther Drug Monit 2008; 30: 474-482. 14. Loscher W and Potschka H. Role of multidrug transporters in pharmacoresistance to

Open access
in PRILOZI
Effects of Short Term Alendronate Administration on Bone Mineral Density in Patients with Chronic Kidney Disease

from kidney disease: improving global outcomes (KDIGO). Kidney Int 2006; 69: 1945-53. 4. Ersoy FF, Passadakis SP, Tam P, Mammos ED, Katopodis PK, Ozener C et al. Bone mineral density and its correlation with clinical and laboratory factors in chronic peritoneal dialysis patients. J Bone Miner Metab 2006; 24(1): 79-86. 5. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996; 18(2) : 75-85. 6. Rodan GA, Fleisch HA. Bisphosphonates: Mechanisms of action. J Clin Invest 1996; 97: 2692-6. 7. Liberman UA, Weiss SR, Broll J

Open access
in PRILOZI
Pharmacogenetics and Antipsychotic Treatment Response/ Фармакогенетски Тестирања И Одговор Кон Третман Со Антипсихотоци

. Nikisch G, Eap CB and Baumann P. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacol Res. 2008; 58: 344-347. 43. Uhr M, Grauer MT, Yassouridis A and Ebinger M. Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls. J Psychiatr Res. 2007; 41: 179-188. 44. Gex-Fabry M, Eap CB, Oneda B, Gervasoni N, Aubry JM, Bondolfi G, et al. CYP2D6 and ABCB1 genetic

Open access
in PRILOZI
Evaluation of the Role of ABCB1gene Polymorphic Variants on Psychiatric Disorders Predisposition in Macedonian Population

. Risperidone and Paliperidone Inhibit P-Glycoprotein Activity In Vitro Neuropsychopharmacology. 2007; 32: 757–764. 31. Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002; 12: 437–450. 32. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters inthe pharmacokinetics of drugs. Pharmacol Ther. 2006 Nov;112(2):457-73. Review. 33. Kimchi-Sarfaty C, Marple AH, Shinar S

Open access
in PRILOZI
Antidepressant drugs for older patients on polypharmacy: a systematic review reveals best evidence for sertraline

to add that there are few possibilities that the inhibition of any single isoform could cause clinically significant changes in the pharmacokinetics of sertraline ( Obach et al. 2005 ). These important pharmacokinetic properties of sertraline show that it has a small number of possible clinically important DDIs in real clinical practice. Despite the fact that these pharmacokinetic properties are important, it is clear that sertraline cannot be used in all older patients on polypharmacy because antidepressants have different mechanisms of action that are very

Open access